Appetite Disorders in Uremia

Journal of Renal Nutrition

Volumn 18, Issue 1, 2008, Pages 107-113

  Carrero, Juan Jesús ^a   Aguilera, Abelardo ^b   Stenvinkel, Peter ^a   Gil, Fernando ^b   Selgas, Rafael ^b   Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; LEPTIN; NITRIC OXIDE;

ANOREXIA; APPETITE; ARTICLE; BLOOD; EATING DISORDER; HOMEOSTASIS; HUMAN; INTESTINE ABSORPTION; PATHOPHYSIOLOGY; PHYSIOLOGY; UREMIA;

ANOREXIA; APPETITE; CYTOKINES; EATING DISORDERS; HOMEOSTASIS; HUMANS; INTESTINAL ABSORPTION; LEPTIN; NITRIC OXIDE; UREMIA;

EID: 37049017129     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2007.10.022     Document Type: Article

References (51)

1. Qureshi A.R., Alvestrand A., Divino-Filho J.C., et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13 Suppl 1 (2002) S28-S36
2. Stenvinkel P., Heimburger O., Paultre F., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 (1999) 1899-1911
3. Stenvinkel P., Heimburger O., Lindholm B., et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 15 (2000) 953-960
4. Bossola M., Tazza L., Giungi S., and Luciani G. Anorexia in hemodialysis patients: an update. Kidney Int 70 (2006) 417-422
5. Aguilera A., Selgas R., Diez J.J., et al. Anorexia in end-stage renal disease: pathophysiology and treatment. Expert Opin Pharmacother 2 (2001) 1825-1838
6. Bergstrom J. Regulation of appetite in chronic renal failure. Miner Electrolyte Metab 25 (1999) 291-297
7. Carrero J.J., Qureshi A.R., Axelsson J., et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 85 (2007) 695-701
8. Burrowes J.D., Larive B., Chertow G.M., et al. Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrol Dial Transplant 20 (2005) 2765-2774
9. Kalantar-Zadeh K., Block G., McAllister C.J., et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80 (2004) 299-307
10. Bossola M., Muscaritoli M., Tazza L., et al. Variables associated with reduced dietary intake in hemodialysis patients. J Ren Nutr 15 (2005) 244-252
11. Burrowes J.D., Larive B., Cockram D.B., et al. Effects of dietary intake, appetite, and eating habits on dialysis and non-dialysis treatment days in hemodialysis patients: cross-sectional results from the HEMO study. J Ren Nutr 13 (2003) 191-198
12. Stricker E.M. Biological bases of hunger and satiety: therapeutic implications. Nutr Rev 42 (1984) 333-340
13. Keshaviah P.R., Nolph K.D., and Van Stone J.C. The peak concentration hypothesis: a urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Perit Dial Int 9 (1989) 257-260
14. Anderstam B., Mamoun A.H., Sodersten P., et al. Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. J Am Soc Nephrol 7 (1996) 2453-2460
15. Mamoun A.H., Sodersten P., Anderstam B., and Bergstrom J. Evidence of splanchnic-brain signaling in inhibition of ingestive behavior by middle molecules. J Am Soc Nephrol 10 (1999) 309-314
16. Stenvinkel P., and Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15 (2002) 329-337
17. Suliman M.E., Qureshi A.R., Stenvinkel P., et al. Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am J Clin Nutr 82 (2005) 342-349
18. Stenvinkel P., Ketteler M., Johnson R.J., et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67 (2005) 1216-1233
19. Diez J.J., Iglesias P., Fernandez-Reyes M.J., et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 62 (2005) 242-249
20. Witasp A., Nordfors L., Lindholm B., and Stenvinkel P. Use of single-nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype. J Ren Nutr 17 (2007) 17-22
21. Cheung W., Yu P.X., Little B.M., et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 115 (2005) 1659-1665
22. Aguilera A., Codoceo R., Bajo M.A., et al. Eating behavior disorders in uremia: a question of balance in appetite regulation. Semin Dial 17 (2004) 44-52
23. Aguilera A., Codoceo R., Selgas R., et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 13 (1998) 1476-1483
24. Cangiano C., Laviano A., Muscaritoli M., et al. Cancer anorexia: new pathogenic and therapeutic insights. Nutrition 12 (1996) S48-S51
25. Brenner D.A., Buck M., Feitelberg S.P., and Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 85 (1990) 248-255
26. Vallance P., Leone A., Calver A., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
27. Squadrito F., Calapai G., Altavilla D., et al. Central serotoninergic system involvement in the anorexia induced by NG-nitro-L-arginine, an inhibitor of nitric oxide synthase. Eur J Pharmacol 255 (1994) 51-55
28. Ando T., and Dunn A.J. Mouse tumor necrosis factor-alpha increases brain tryptophan concentrations and norepinephrine metabolism while activating the HPA axis in mice. Neuroimmunomodulation 6 (1999) 319-329
29. Stenvinkel P., Pecoits-Filho R., and Lindholm B. Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease?. Adv Ren Replace Ther 10 (2003) 332-345
30. Nordfors L., Lonnqvist F., Heimburger O., et al. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 54 (1998) 1267-1275
31. Stenvinkel P. Leptin-a new hormone of definite interest for the nephrologist. Nephrol Dial Transplant 13 (1998) 1099-1101
32. Converse Jr. R.L., Jacobsen T.N., Toto R.D., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327 (1992) 1912-1918
33. Isse T., Ueta Y., Serino R., et al. Effects of leptin on fasting-induced inhibition of neuronal nitric oxide synthase mRNA in the paraventricular and supraoptic nuclei of rats. Brain Res 846 (1999) 229-235
34. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353 (1999) 1838-1842
35. Li J.Y., Finniss S., Yang Y.K., et al. Agouti-related protein-like immunoreactivity: characterization of release from hypothalamic tissue and presence in serum. Endocrinology 141 (2000) 1942-1950
36. Chaki S., Hirota S., Funakoshi T., et al. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor. J Pharmacol Exp Ther 304 (2003) 818-826
37. Nonogaki K., Ohashi-Nozue K., and Oka Y. A negative feedback system between brain serotonin systems and plasma active ghrelin levels in mice. Biochem Biophys Res Commun 341 (2006) 703-707
38. Aguilera A., Cirugeda A., Amair R., et al. Ghrelin plasma levels and appetite in peritoneal dialysis patients. Adv Perit Dial 20 (2004) 194-199
39. Geary N. Estradiol, CCK and satiation. Peptides 22 (2001) 1251-1263
40. Geary N. Sex differences in disease anorexia. Nutrition 17 (2001) 499-507
41. Lyons P.M., Truswell A.S., Mira M., et al. Reduction of food intake in the ovulatory phase of the menstrual cycle. Am J Clin Nutr 49 (1989) 1164-1168
42. Barr S.I., Janelle K.C., and Prior J.C. Energy intakes are higher during the luteal phase of ovulatory menstrual cycles. Am J Clin Nutr 61 (1995) 39-43
43. Gayle D.A., Desai M., Casillas E., et al. Gender-specific orexigenic and anorexigenic mechanisms in rats. Life Sci (2006)
44. Lennie T.A. Sex differences in severity of inflammation-induced anorexia and weight loss. Biol Res Nurs 5 (2004) 255-264
45. Eckel L.A. Estradiol: a rhythmic, inhibitory, indirect control of meal size. Physiol Behav 82 (2004) 35-41
46. Lu H., Lei X., and Klaassen C. Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats. Kidney Int (2006)
47. Chen Z., Bassford T., Green S.B., et al. Postmenopausal hormone therapy and body composition-a substudy of the estrogen plus progestin trial of the Women's Health Initiative. Am J Clin Nutr 82 (2005) 651-656
48. Stenvinkel P., Barany P., Chung S.H., et al. A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. Nephrol Dial Transplant 17 (2002) 1266-1274
49. Rammohan M., Kalantar-Zadeh K., Liang A., and Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr 15 (2005) 345-355
50. Boccanfuso J.A., Hutton M., and McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 10 (2000) 36-43
51. Costero O., Bajo M.A., del Peso G., et al. Treatment of anorexia and malnutrition in peritoneal dialysis patients with megestrol acetate. Adv Periton Dial 20 (2004) 209-212